Customs Valuation When You Pay a Partner Service Fee: First Sale, R&D, Dutiability

When does a service fee paid to a supplier or partner become part of dutiable value?

It depends on whether the service is an assist under 19 U.S.C. 1401a and on whether the service was undertaken in the United States or abroad. Assists (defined as items or services provided by the buyer to the seller free of charge or at reduced cost for use in producing the imported merchandise) are part of dutiable value. Service fees for R&D, engineering, design, or artwork performed in the United States are typically not dutiable. Service fees for the same activities performed outside the United States are typically dutiable as assists. Service fees that are part of the buyer-seller commercial transaction for the imported goods themselves (commissions, royalties tied to imported goods) may also be dutiable depending on the specific arrangement.

What is first sale valuation and when does it apply?

First sale valuation allows the customs value to be based on the first sale price in a multi-tier transaction (e.g., manufacturer to middleman to U.S. importer) rather than the price the U.S. importer ultimately pays. To qualify, the first sale must meet specific requirements including being a bona fide sale, being for export to the United States, and meeting the value documentation standards. First sale is most valuable for pharma, biotech, and other high-value industries where the multi-tier markup is significant. The CBP guidance and ruling framework on first sale is detailed; importers should verify qualification per their specific transaction structure.

---

TL;DR: Customs valuation under 19 U.S.C. 1401a generally uses transaction value (the price actually paid or payable for the imported merchandise) plus required additions. Service fees paid to suppliers or related parties become part of dutiable value when they meet the assist test or are otherwise dutiable additions. Specifically, R&D and engineering services performed outside the United States are typically dutiable assists; R&D and engineering services performed in the United States are typically not. First sale valuation allows customs value based on an earlier sale in a multi-tier transaction, which can materially reduce dutiable value for high-markup industries (pharma, biotech, branded consumer goods). The CBP guidance and ruling framework is detailed; importers in industries where service fees and multi-tier transactions are common (pharma, biotech, branded apparel, technology) should run specific analysis on their valuation positions. For Chinese-origin importers operating Mexico nearshoring with related-party transactions, service fee valuation is particularly important because related-party transfer pricing affects the underlying transaction value before considering services. GingerControl's compliance audit service supports customs valuation analysis including first sale qualification review and assist analysis. CBP collected $225.8 billion in duties, taxes, and fees in FY 2025, with valuation adjustments contributing to audit findings.

Last updated: May 2026

---

The Transaction Value Framework

U.S. customs valuation under 19 U.S.C. 1401a generally uses the transaction value method as the primary valuation basis. Transaction value is defined as the price actually paid or payable for the merchandise when sold for exportation to the United States, plus required statutory additions.

Required statutory additions include:

• Packing costs incurred by the buyer
• Selling commissions incurred by the buyer (not buying commissions)
• Assists (items or services provided by the buyer to the seller for use in producing the imported merchandise)
• Royalties and license fees related to the imported merchandise that the buyer must pay as a condition of sale
• Proceeds of subsequent resale that accrue to the seller

Service fees paid to suppliers or related parties may fall within one or more of these categories. The analysis depends on the specific arrangement.

The Assist Analysis

Assists under 19 U.S.C. 1401a(h)(1) are defined as items or services that the buyer provides directly or indirectly, free of charge or at reduced cost, for use in connection with the production or sale for export of the imported merchandise. Five categories of assists:

1. Materials, components, parts, and similar items incorporated in the imported merchandise
2. Tools, dies, molds, and similar items used in producing the imported merchandise
3. Merchandise consumed in producing the imported merchandise
4. Engineering, development, artwork, design work, and plans and sketches undertaken outside the United States and necessary for the production of the imported merchandise
5. Sample products for use in connection with the production or sale

For service fees, the most relevant category is the fourth: engineering, development, artwork, design work, and plans and sketches.

Critical distinction: Engineering, development, artwork, design, plans, and sketches undertaken outside the United States are dutiable assists. The same activities undertaken in the United States are not assists and are not part of dutiable value.

This U.S.-vs-foreign distinction is the most important practical rule for service fee valuation.

When R&D Services Are Dutiable vs. Not Dutiable

Pharma, biotech, technology, and other R&D-intensive industries frequently involve service fee arrangements between U.S. importers and foreign suppliers or related parties. The dutiability question:

Not dutiable (U.S.-performed R&D):

• R&D conducted at U.S. research facilities
• Engineering design developed by U.S. engineering teams
• Artwork and design work created in U.S. design studios
• Clinical trials conducted in U.S. clinical sites
• Regulatory submission preparation done in U.S. regulatory affairs offices

Dutiable (foreign-performed R&D as assists):

• R&D conducted at foreign research facilities provided free or at reduced cost to the foreign supplier
• Engineering design developed by foreign engineering teams provided as assist
• Artwork created outside the U.S. as assist
• Foreign clinical trials when the trial output is used in producing the imported product
• Foreign regulatory submission preparation when provided as assist

The distinction often determines whether a multi-million-dollar service fee is fully dutiable (adding to landed cost across thousands of import entries) or excluded from valuation (significant duty savings).

For pharma and biotech, the analysis often involves:

• Where the clinical trials were conducted
• Where the manufacturing process development occurred
• Where the analytical methods were developed
• Where the technology transfer documentation was created

Each location matters for the dutiability determination.

First Sale Valuation

First sale valuation is an alternative valuation approach available for multi-tier transactions where merchandise passes through one or more middlemen between the original manufacturer and the U.S. importer.

The mechanics:

• Standard valuation: Customs value is based on the price the U.S. importer pays to the immediate seller (typically the middleman)
• First sale valuation: Customs value is based on the earlier sale price between the manufacturer and the middleman

The savings: the markup added by the middleman is excluded from dutiable value.

Qualification requirements based on CBP precedent and the Supreme Court's Nissho Iwai America Corp. v. United States framework:

1. The first sale must be a bona fide sale (genuine commercial transaction with title transfer, risk of loss transfer, etc.)
2. The first sale must be for export to the United States (the goods must be clearly destined for U.S. import)
3. The first sale price must be the price actually paid for the goods
4. Documentation must support each element

First sale is most valuable in industries with significant multi-tier markup:

• Pharma and biotech. Markups between manufacturer and U.S. importer can be substantial.
• Branded apparel. Brand owner markups over manufacturer prices can be material.
• Technology. Component manufacturer markups over assembled product manufacturer.
• Consumer goods. Trading company markups over actual factory prices.

For qualifying transactions, first sale valuation can reduce dutiable value by 20-50% or more, with corresponding duty savings.

Common Pharma/Biotech Service Fee Scenarios

Scenario 1: U.S. Importer Pays Indian CMO for Manufacturing

A U.S. pharma importer pays an Indian contract manufacturing organization (CMO) for manufacturing finished pharmaceuticals. The manufacturing fee is the transaction value. R&D supporting the manufacturing was conducted at U.S. research facilities.

Treatment: Transaction value is the manufacturing fee. U.S.-performed R&D is not an assist. Service fee for U.S. R&D is not part of dutiable value.

Scenario 2: U.S. Importer Pays Indian CMO and Funds Indian R&D

Same as Scenario 1, but the U.S. importer also funds Indian R&D facility operations that develop the manufacturing process used by the CMO. The Indian R&D output is then provided to the CMO.

Treatment: The Indian R&D output provided to the CMO may be a dutiable assist if it constitutes engineering, development, design work, or plans necessary for production of the imported pharmaceutical.

Scenario 3: Multi-Tier Pharma Transaction

A Chinese API manufacturer sells to a Hong Kong trading company, which sells to a U.S. importer. The first sale (Chinese manufacturer to Hong Kong trader) is at $40/kg; the second sale (Hong Kong trader to U.S. importer) is at $60/kg.

Treatment: If first sale qualification is established, customs value can be based on $40/kg rather than $60/kg, reducing dutiable value by $20/kg.

Common Biotech Service Fee Scenarios

Scenario 1: U.S. Biotech Imports From European Contract Research Organization

A U.S. biotech imports biological samples from a European CRO that conducted research at the U.S. biotech's direction. The CRO charges the U.S. biotech a service fee.

Treatment: The service fee for European CRO work may include both research services (potentially dutiable as foreign-performed R&D assist) and the supply of materials. Analysis depends on the contract structure and what specifically the fee covers.

Scenario 2: Related-Party Transfer Pricing

A U.S. biotech subsidiary of a foreign pharma parent imports finished biologics from related-party foreign manufacturing. The transfer pricing arrangement was set by transfer pricing study.

Treatment: Related-party transactions trigger additional valuation scrutiny under 19 CFR 152.103. The related-party transaction value may need to be tested against test values (similar arm's-length sales) to qualify as transaction value. Reconciliation may be required.

How GingerControl Supports Valuation Analysis

GingerControl's compliance audit service supports:

• First sale qualification review for multi-tier transactions
• Assist analysis for service fee arrangements
• Related-party transaction value support for transfer pricing-based valuation
• Reconciliation strategy for transactions with pending value determinations
• Valuation documentation retention for audit defense

The work is conducted by the compliance team with multilingual support (Mandarin, Cantonese, Spanish, English) for international operations and supplier coordination.

Frequently Asked Questions

What is an assist under U.S. customs law?

An assist is an item or service that the buyer provides directly or indirectly, free of charge or at reduced cost, for use in producing or selling the imported merchandise. Assists include materials, tools, consumables, foreign-performed engineering/design/artwork, and samples. Assists are part of dutiable value.

Are U.S.-performed R&D services dutiable?

Generally no. U.S.-performed engineering, development, artwork, design, plans, and sketches are not assists and are not part of dutiable value, even when they support production of imported merchandise. The U.S.-vs-foreign distinction is the critical factor.

What is first sale valuation?

First sale valuation allows customs value to be based on an earlier sale in a multi-tier transaction rather than the price the U.S. importer ultimately pays. The first sale must be a bona fide sale for export to the United States with appropriate documentation. First sale typically reduces dutiable value by the markup added by middlemen.

Does first sale apply to pharma imports?

Yes, when the qualification requirements are met. First sale is particularly valuable for pharma because middleman markups in pharma multi-tier transactions can be substantial. The qualification analysis is case-specific.

How are related-party transactions valued?

Related-party transactions can use transaction value if the relationship did not influence the price, demonstrated through circumstances of sale or test values. The reconciliation process under 19 CFR Part 174 addresses adjustments that may apply.

What documentation supports first sale valuation?

Documentation includes the manufacturer-to-middleman invoice, evidence of the first sale terms, evidence the goods were destined for U.S. import at first sale, and evidence that all transaction value requirements are met. Specific documentation requirements depend on the transaction structure.

How does GingerControl support customs valuation analysis?

GingerControl's compliance audit service supports first sale qualification review, assist analysis, related-party transaction value support, and valuation documentation retention. The work is most valuable for pharma, biotech, branded consumer goods, and technology industries where multi-tier markup or service fee arrangements are material.

What happens if CBP rejects my first sale valuation?

CBP may require additional documentation or may determine that first sale qualification is not met. Rejected first sale claims revert to standard transaction value (typically the price the U.S. importer paid), with additional duty owed. The protest path is available for contested valuation decisions.

---

Get Your Valuation Analysis Right

If your customs valuation depends on first sale qualification, assist analysis, or related-party transfer pricing, the dutiability questions can materially affect landed cost. The analysis is fact-specific and benefits from compliance review before filing decisions are made.

Get a no-cost valuation review from GingerControl. The review evaluates your specific valuation positions, identifies first sale qualification opportunities, and recommends documentation improvements for audit defense.

GingerControl is not just a tool. We work with pharma, biotech, branded consumer goods, and technology importers on customs valuation analysis, first sale qualification, and ongoing compliance program development. Talk to our team about your customs valuation situation.

---

References

[REF 1] 19 U.S.C. 1401a, Value Data cited: Customs valuation framework and assist definitions Source: 19 U.S.C. 1401a

[REF 2] 19 CFR 152, Classification and Appraisement of Merchandise Data cited: CBP valuation regulations Source: 19 CFR Part 152

[REF 3] 19 CFR 152.103, Transaction Value Data cited: Transaction value framework and related-party considerations Source: 19 CFR 152.103

[REF 4] CBP Informed Compliance Publication, Customs Valuation Data cited: CBP valuation guidance Source: CBP Valuation Publication

[REF 5] Nissho Iwai America Corp. v. United States Data cited: First sale valuation framework Source: Federal Circuit precedent

[REF 6] WTO Customs Valuation Agreement Data cited: International framework for customs valuation Source: WTO Customs Valuation

[REF 7] U.S. Customs and Border Protection, Trade Statistics Data cited: $225.8 billion in duties, taxes, and fees collected in FY 2025 Source: CBP Trade Statistics Published: 2025